开发一项简单的临床风险评分,用于IBRUTINIB相关的心房动
Tyler A Jacobson1, Graham Peigh2, Ruchi Patel2
1Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
概括
治疗B细胞恶性瘤的易布鲁替尼可能会导致心房动 (AF). 一个新的简单风险评分,包括阻塞性睡眠呼吸暂停和心力衰竭等因素,显示出预测这种易布鲁替尼相关的AF的前景.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 易布鲁替尼是布鲁顿的氨酸激酶 (BTK) 抑制剂,用于B细胞恶性瘤.
- 心房动 (AF) 是一种已知易布鲁替尼治疗的副作用.
- 预测易布鲁替尼相关的AF (IAAF) 对于患者管理至关重要.
研究的目的:
- 评估现有的AF风险评分在预测事件IAAF中的表现.
- 开发和验证IAAF预测的新临床风险评分.
主要方法:
- 对167名接受IBRUTINIB治疗的患者进行了回顾性研究,这些患者以前没有AF.
- 评估已建立的AF风险模型的预测能力.
- 开发新的IAAF风险评分,使用后勤回归和通过AUC分析进行比较.
主要成果:
- 14.4%的患者在24个月内发展出IAAF.
- 高血压,糖尿病,心力衰竭和阻塞性睡眠呼吸暂停与IAAF有关.
- 一个新的风险评分 (OSA,HFrEF,DM,高脂血症) 达到0.77的AUC,超过现有模型的表现.
结论:
- 国际田联的风险因素与一般的AF风险因素相似.
- 现有的AF风险模型对IAAF具有适度的预测能力.
- 一个新的简单的临床风险评分显示了改善IAAF预测的潜力,需要进一步验证.
相关概念视频
Clinical Trials: Overview
2.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.6K
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
Assessment of blood pressure in brachial artery(two-step method)
643
Measuring blood pressure is a fundamental skill in healthcare that aids in diagnosing and monitoring hypertension and other cardiovascular conditions. An aneroid sphygmomanometer, commonly used in clinical settings, offers a manual and precise method for blood pressure measurement. The technique for using this instrument involves specific steps that must be carefully executed to ensure accuracy. The following detailed description outlines a two-step technique for assessing blood pressure using...
643
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
110
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
110
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
695
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
695


